The latest FDA drug approvals include traditional approval of pralsetinib for metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer, a monoclonal antibody for infants and children at severe risk of respiratory syncytial virus (RSV), the first treatment for people two years of age and older with the viral skin infection molluscum contagiosum, and a treatment for an eyelid disease called Demodex blepharitis.
Source: Drug Industry Daily